NSEReply to Clarification- Financial results2d ago · 23 Sept 2026, 11:04 am
Reply to Clarification- Financial results
Supriya Lifescience Limited · SUPRIYA
✦ AI SummaryResults
Supriya Lifescience Limited has clarified the absence of segment details in their quick results submitted on August 13, 2026, attributing it to a technical error. The company has a track record of timely and accurate disclosures and reaffirms their commitment to full compliance with the SEBI (LODR) Regulations, 2015.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk3/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Attachments (1)
📄pdf
Download →
SUPRIYA_05092026153449_ReplytoNEAPS05092026.pdf
View document text
September 05, 2026
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA
Dear Sir/Madam,
Subject: Clarification for Financial results - SUPRIYA
Ref: Board Meeting dated August 13, 2026
With reference to your email dated September 02, 2026, seeking clarification on below mentioned query:
With Reference to the absence of segment details in the quick results submitted by the Company on
August 13, 2026, we wish to submit the following clarification:
The Company operates in a single business segment, namely Pharmaceuticals.
We further wish to state that, at the time of submission of Outcome, we had selected the appropriate
option under segment column viz. Single Segment, however the same is not being displayed post
submission.
The omission of segment information in the said submission was due to a technical error, which occurred
inadvertently. The Company will investigate the error to resolve it.
We express our sincere regret for the inadvertent error and respectfully request that this explanation be
taken on record.
We reaffirm our commitment to full compliance with the SEBI (LODR) Regulations, 2015. The Company
has a track record of timely and accurate disclosures and remains dedicated to upholding these practices
in all future filings.
Thank you for your kind attention to this matter.
Yours faithfully
For Supriya Lifescience Limited
Prachi Sathe
Company Secretary & Compliance Officer
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE